RNF113B

Across TCGA pan-cancer cohorts, RNF113B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RNF113B data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RNF113B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNF113B expression acts as an unfavorable survival marker.

PDAC, LUAD, and HNSC are the cancer types where RNF113B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.456	0.729	.010	14	view →
LUAD	OS	Quartile	II,III,IV	0.308	0.693	.018	4	view →
HNSC	DFS	Tertile	All	0.588	0.902	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RNF113B–PDAC (DFS)

Open the PDAC breakdown →